In 2007, as part of their philanthropic effort in multidrug-resistance tuberculosis, Eli Lilly and Company announced The Lilly TB Drug Discovery Initiative. This unique endeavor is designed to accelerate discovery and development of new drugs to fight TB. The ultimate aim is to make treatment of TB more effective, accessible, and affordable.
The partnership will be based in Seattle, Washington, at the Infectious Disease Research Institute (IDRI). Partners include:
If you have candidate compounds or validated targets that may be suitable for TB drug development, contact Dr. Gail Cassell at Lilly: firstname.lastname@example.org or Dr. Barbara Laughon at NIAID: email@example.com or +1 301-402-0138.
Statement of Christine F. Sizemore, Ph.D., Barbara E. Laughon, Ph.D., and Anthony S. Fauci, M.D., on World TB Day—Mar. 24, 2008
Lilly Unveils Ambitious Partnership for Tuberculosis Drug Discovery—June 13, 2007 (Eli Lilly and Company)
back to top
Last Updated January 03, 2012